Verve Therapeutics, Inc. VERV
Set alert
At close · Jul 25
52-week range unavailable
- YTD
- +97.34%
- 1 year
- +57.20%
- Open
- 11.13
- Prev close
- 11.13
- Mkt cap
- 499.52M
- Vol
- 10.31M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.13
- High
- 11.13
- Forward P/E
- -2.04
- Beta
- 1.76
- Short ratio
- 11.25
- Inst. own
- 97.87%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.76
- 200-d avg
- 6.48
- 1y target
- 26.20
Key statistics
- Market cap
- 499.52M
- Enterprise value
- 17.31M
- Trailing P/E
- 0.00
- Forward P/E
- -2.04
- PEG ratio
- 0.00
- Price / sales
- 20.48
- Price / book
- 0.98
- EPS (TTM)
- -2.46
- Beta
- 1.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 24.40M
- Revenue growth
- 120.20%
- Free cash flow
- -93.18M
- Total cash
- 539.92M
- Total debt
- 71.25M
- Return on equity
- -40.67%
- Shares outstanding
- 84.66M
- Short % of float
- 25.20%
- 50-day average
- 5.76
- 200-day average
- 6.48
Analyst view
Consensus: buy
- Target (low)
- 14.00
- Target (mean)
- 26.20
- Target (high)
- 40.00
- Strong buy3
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.67322.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 6, 2024 | RBC Capital | main | Outperform | Outperform |
| Nov 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2024 | RBC Capital | main | Outperform | Outperform |
About Verve Therapeutics, Inc.
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vervetx.com
News
- Three Biotechs That Are Top Takeover Targets
- What's Happening With French Biotech Abivax Stock On Wednesday?
- Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
- Lilly and Verve announce expiration of Verve tender offer
- 3 Bullish Biotech Stocks With Explosive Growth Trends
- Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
- $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)
- VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV
- Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
- Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly
Your note
Sign in to keep a note on VERV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADELMAN BURT A | Director | Stock Gift | Sep 17, 2023 | 0 |
| ASHE ANDREW D | President | Purchase | May 13, 2024 | 342,509 |
| DORVAL ALLISON | Chief Financial Officer | Sale | Dec 1, 2024 | 5,380 |
| KATHIRESAN SEKAR | Chief Executive Officer | Stock Gift | Dec 3, 2024 | 675,502 |
| NICKERSON JOAN | Officer | Sale | Apr 1, 2024 | 8,659 |
| YESHWANT KRISHNA | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 30, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alphabet Inc. | 14.59% | 12,349,086 | 72.86M | Sep 29, 2024 |
| Blackrock Inc. | 8.59% | 7,276,347 | 42.93M | Sep 29, 2024 |
| Millennium Management Llc | 5.86% | 4,963,181 | 29.28M | Sep 29, 2024 |
| State Street Corporation | 5.02% | 4,253,217 | 25.09M | Sep 29, 2024 |
| Vanguard Group Inc | 4.73% | 4,005,161 | 23.63M | Sep 29, 2024 |
| Casdin Capital, LLC | 4.72% | 3,995,571 | 23.57M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.86% | 2,424,887 | 14.31M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.54% | 2,153,946 | 12.71M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.16% | 1,831,838 | 10.81M | Oct 30, 2024 |
| Price (T.Rowe) Small-Cap Value Fund | 1.47% | 1,241,535 | 7.33M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 986,799 | 5.82M | Sep 29, 2024 |
| College Retirement Equities Fund-Stock Account | 1.03% | 868,910 | 5.13M | Sep 29, 2024 |